Skip to main content

Table 5 Survival and toxicities of patients undergoing late course accelerated hyper-fractionated radiotherapy for esophageal squamous cell carcinoma

From: Elective lymph node irradiation late course accelerated hyper-fractionated radiotherapy plus concurrent cisplatin-based chemotherapy for esophageal squamous cell carcinoma: a phase II study

First author Study No. of patients TNM stage Treatment scheme Overall survival Locol control Treatment failure Toxicity (Grade≥3)
Shi XH [18] Prospective 43 T1-4N0-1M0 41.4Gy/23fx followed by 27Gy/18fx with 1.5Gy, bid 5-year 34% 5-year 55% LR 41.8% (18/43) PI 27.9% (12/43)
DM 18.6% (8/43) EI 34.9% (15/43)
Wang Y [19] Prospective 52 T1-4N0-1M0 41.4Gy/23fx followed by 27Gy/18fx with 1.5Gy,bid 1-year 80.0% 1-year 80.7% LRF 13.5% (7/52) PI 3.8% (2/52)
     EI 9.6% (5/52)
  3-year 41.2% 3-year 57.1% DM 15.4% (8/52) ES 1.9 % (1/52)
PF 0% (0/48)
     EH 3.8% (2/52)
Zhao KL [20] Retrospective 56 T1-2N0M0 41.4Gy/23fx followed by 27Gy/18fx with 1.5Gy, bid 1-year 90.9% 1-year 90.9% LR 12.5% (7/56) PI 5.4 % (3/56)
3-year 54.6% 3-year 84.5% DM 21.4% (12/56) EI 10.7 % (6/56)
ES 1.8 % (/56)
5-year 47.8 % 5-year 84.5 % PF 1.8 % (/56)
Zhao KL [21] Retrospective 201 T1-4N0-1M0 41.4Gy/23fx followed by 27Gy/18fx with 1.5Gy, bid 1-year 73%, 1-year 77% LRF 38.4% (77/201) EI 15.4% (31/201)
    PI 7.0% (14/201)
3-year 34%, 3-year 58% DM 34.9% (70/201) EF 0.5% (1/201)
5-year 26% 5-year 56%  
Zhao KL [22] Prospective 54 T1-4N0-1M0 41.4Gy/23fx followed by 27Gy/18fx with 1.5Gy, bid Plus ≥2 cycles of CHT with cisplatin+5-FU 1-year 67%, 1-year 84% LRF 25.9% (14/54) EI 24.1% (13/54)
PI 5.5% (3/54)
3-year 44%, 3-year 74% PF 14.8% (8/54)
5-year 40% 5-year 67% DM 24% (13/54) ES 3.7% (2/54)
Wang JH [23] Prospective 48 T1-4N0-1M0 40Gy/20fx followed by 21–27 Gy/14-18fx with 1.5Gy, bid 1-year 79.2% 1-year 81.3% LR 35.4% (17/48) PI 33.33% (16/48)
EI 27.1% (13/48)
3-year 43.8% 3-year 50.0% DM 16.7% (8/48) ES 14.6% (7/48)
PF 0% (0/48)
  1. Note: distant metastasis–DM; local recurrence–LR; locoregional failure–LRF; esophagitis–EI; pneumonitis–PI; pulmonary fibrosis–PF; esophageal stenosis–ES; esophageal hemorrhage–EH; esophagus fistula–EF; fractions–fx; twice a day–bid; concurren chemotherapy–CHT.